Cargando…
SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor
Background: Euglycemic diabetic ketosis acidosis (DKA) is a possible adverse event with sodium-glucose cotransporter-2 inhibitor (SGLT2i). A number of contributing factor(s) have been identified precipitating DKA with the use of SGLT2i. Here we present three cases developing DKA on SGLT2i. Clinical...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553402/ http://dx.doi.org/10.1210/js.2019-SUN-188 |
_version_ | 1783424811660214272 |
---|---|
author | Attia, Jonven Elsheikh, Arwa Shafiq, Ismat Valle, Valle |
author_facet | Attia, Jonven Elsheikh, Arwa Shafiq, Ismat Valle, Valle |
author_sort | Attia, Jonven |
collection | PubMed |
description | Background: Euglycemic diabetic ketosis acidosis (DKA) is a possible adverse event with sodium-glucose cotransporter-2 inhibitor (SGLT2i). A number of contributing factor(s) have been identified precipitating DKA with the use of SGLT2i. Here we present three cases developing DKA on SGLT2i. Clinical Case 1: A 64-year-old Caucasian female with history of type 2 diabetes (T2DM) presented to the emergency department (ED) with nausea, vomiting and abdominal pain 24 hours after evisceration of her eyes with implantation. She was on Jardiance for the last 3 months. Laboratory evaluation revealed a serum glucose of 95 mg/dl (n:70-100mg/dL), pH: 7.3 (n: 7.32 - 7.42), anion gap of 22 (n:7 - 16), carbon dioxide of 10 mmol/L (n: 20 - 28 mmol/L ), beta- hydroxybutyrate of 4.88 mmol/L (n: 0.02 - 0.27 mmol/L), plasma lactate of 0.9 mmol/L (n: 0.5 - 2.2 mmol/L) and urinalysis of glucose greater than 500 mg/dl and plus ketone. She was treated for euglycemic DKA with an insulin drip and intravenous fluids. She was discharge on insulin. Glutamic acid decarboxylase and islet cell antibodies were negative, c-peptide and insulin levels were normal. Perioperative continuation of Jardiance was attributed to be the cause of euglycemic DKA. Clinical Case 2: A 62-year-old male with T2DM presented to the ED for persistent nausea and vomiting. He has been on Jardiance for almost 8 months. A month ago, he started following intermittent fasting diet. Laboratory evaluation was consistent with euglycemic DKA. He had elevated Glutamic acid decarboxylase antibody thus was diagnosed with LADA. Intermittent fasting and LADA was attributed to be the cause euglycemic DKA. Clinical Case 3: 77-years-old male with T2DM well controlled on Jardiance, presented to the ED with nausea and abdominal pain. CT scan of the abdomen revealed gallbladder wall thickness and sludge with pericholecystic fluid. He underwent a percutaneous drainage and antibiotics treatment. A week into his hospitalization, he clinically deteriorated with laboratory findings consistent euglycemic DKA. Systemic illness was considered to be the underlying factor precipitating DKA. Conclusion: SGLT2i are reported to cause euglycemic DKA with underlying contributing factor(s). Physician and patients should be aware of the contributing factors precipitating DKA. Taking a thorough history, defining the type of diabetes, dietary education and discontinuation of medication in the setting of procedure/illness can prevent DKA and potential serious outcomes. |
format | Online Article Text |
id | pubmed-6553402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65534022019-06-13 SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor Attia, Jonven Elsheikh, Arwa Shafiq, Ismat Valle, Valle J Endocr Soc Diabetes Mellitus and Glucose Metabolism Background: Euglycemic diabetic ketosis acidosis (DKA) is a possible adverse event with sodium-glucose cotransporter-2 inhibitor (SGLT2i). A number of contributing factor(s) have been identified precipitating DKA with the use of SGLT2i. Here we present three cases developing DKA on SGLT2i. Clinical Case 1: A 64-year-old Caucasian female with history of type 2 diabetes (T2DM) presented to the emergency department (ED) with nausea, vomiting and abdominal pain 24 hours after evisceration of her eyes with implantation. She was on Jardiance for the last 3 months. Laboratory evaluation revealed a serum glucose of 95 mg/dl (n:70-100mg/dL), pH: 7.3 (n: 7.32 - 7.42), anion gap of 22 (n:7 - 16), carbon dioxide of 10 mmol/L (n: 20 - 28 mmol/L ), beta- hydroxybutyrate of 4.88 mmol/L (n: 0.02 - 0.27 mmol/L), plasma lactate of 0.9 mmol/L (n: 0.5 - 2.2 mmol/L) and urinalysis of glucose greater than 500 mg/dl and plus ketone. She was treated for euglycemic DKA with an insulin drip and intravenous fluids. She was discharge on insulin. Glutamic acid decarboxylase and islet cell antibodies were negative, c-peptide and insulin levels were normal. Perioperative continuation of Jardiance was attributed to be the cause of euglycemic DKA. Clinical Case 2: A 62-year-old male with T2DM presented to the ED for persistent nausea and vomiting. He has been on Jardiance for almost 8 months. A month ago, he started following intermittent fasting diet. Laboratory evaluation was consistent with euglycemic DKA. He had elevated Glutamic acid decarboxylase antibody thus was diagnosed with LADA. Intermittent fasting and LADA was attributed to be the cause euglycemic DKA. Clinical Case 3: 77-years-old male with T2DM well controlled on Jardiance, presented to the ED with nausea and abdominal pain. CT scan of the abdomen revealed gallbladder wall thickness and sludge with pericholecystic fluid. He underwent a percutaneous drainage and antibiotics treatment. A week into his hospitalization, he clinically deteriorated with laboratory findings consistent euglycemic DKA. Systemic illness was considered to be the underlying factor precipitating DKA. Conclusion: SGLT2i are reported to cause euglycemic DKA with underlying contributing factor(s). Physician and patients should be aware of the contributing factors precipitating DKA. Taking a thorough history, defining the type of diabetes, dietary education and discontinuation of medication in the setting of procedure/illness can prevent DKA and potential serious outcomes. Endocrine Society 2019-04-30 /pmc/articles/PMC6553402/ http://dx.doi.org/10.1210/js.2019-SUN-188 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Diabetes Mellitus and Glucose Metabolism Attia, Jonven Elsheikh, Arwa Shafiq, Ismat Valle, Valle SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor |
title | SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor |
title_full | SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor |
title_fullStr | SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor |
title_full_unstemmed | SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor |
title_short | SUN-188 Contributing Factors Precipitation Diabetic Ketoacidosis in Patients Using Sodium-Glucose Cotransporter-2 Inhibitor |
title_sort | sun-188 contributing factors precipitation diabetic ketoacidosis in patients using sodium-glucose cotransporter-2 inhibitor |
topic | Diabetes Mellitus and Glucose Metabolism |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553402/ http://dx.doi.org/10.1210/js.2019-SUN-188 |
work_keys_str_mv | AT attiajonven sun188contributingfactorsprecipitationdiabeticketoacidosisinpatientsusingsodiumglucosecotransporter2inhibitor AT elsheikharwa sun188contributingfactorsprecipitationdiabeticketoacidosisinpatientsusingsodiumglucosecotransporter2inhibitor AT shafiqismat sun188contributingfactorsprecipitationdiabeticketoacidosisinpatientsusingsodiumglucosecotransporter2inhibitor AT vallevalle sun188contributingfactorsprecipitationdiabeticketoacidosisinpatientsusingsodiumglucosecotransporter2inhibitor |